Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1
G Hamilton, B Rath - Expert opinion on drug metabolism & …, 2018 - Taylor & Francis
Introduction: The efficacy of platinum-based chemotherapy for patients with non-small cell
lung cancer (NSCLC) is limited by chemoresistance. Platinum drugs damage DNA by …
lung cancer (NSCLC) is limited by chemoresistance. Platinum drugs damage DNA by …
Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell …
P Krawczyk, K Wojas-Krawczyk, R Mlak… - Folia histochemica …, 2012 - journals.viamedica.pl
Platinum-based chemotherapy is the main type of I-line treatment of advanced and non-
operative NSCLC patients without EGFR gene mutation. The excision repair cross …
operative NSCLC patients without EGFR gene mutation. The excision repair cross …
Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer
C He, Z Duan, P Li, Q Xu, Y Yuan - Anti-Cancer Drugs, 2013 - journals.lww.com
The ERCC5 gene plays an important role in the nucleotide excision repair pathway that
recognizes and removes platinum–DNA adducts. We aimed to examine whether ERCC5 …
recognizes and removes platinum–DNA adducts. We aimed to examine whether ERCC5 …
Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients
The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA
repair and has been linked to resistance to platinum-based anticancer drugs among …
repair and has been linked to resistance to platinum-based anticancer drugs among …
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
Although platinum-based chemotherapy remains the standard treatment for advanced
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …
NSCLC patients, clinical outcomes are poor and most patients develop high-grade toxicities …
Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line …
SH Kim, GW Lee, MJ Lee, YJ Cho, YY Jeong, HC Kim… - Lung Cancer, 2012 - Elsevier
BACKGROUND: First-line platinum-based chemotherapy is currently considered the
standard treatment for unresectable non-small cell lung cancer (NSCLC). However …
standard treatment for unresectable non-small cell lung cancer (NSCLC). However …
Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
I Sullivan, J Salazar, M Majem, C Pallarés, E Del Río… - Cancer letters, 2014 - Elsevier
Genetic variants in DNA repair genes may play a role in the effectiveness of platinum-based
chemotherapy in non-small cell lung cancer (NSCLC). We analyzed 17 SNPs in eight genes …
chemotherapy in non-small cell lung cancer (NSCLC). We analyzed 17 SNPs in eight genes …
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta …
M Yin, J Yan, A Voutsina, C Tibaldi, DC Christiani… - Lung cancer, 2011 - Elsevier
BACKGROUND: The nucleotide excision repair (NER) pathway modulates platinum-based
chemotherapeutic efficacy by removing drug-induced DNA damage. METHODS: To …
chemotherapeutic efficacy by removing drug-induced DNA damage. METHODS: To …
Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer …
C Perez-Ramirez, M Canadas-Garre… - The …, 2019 - nature.com
Chemotherapy based on platinum compounds is the standard treatment for NSCLC patients
with EGFR wild type, and is also used as second line in mutated EGFR patients …
with EGFR wild type, and is also used as second line in mutated EGFR patients …
Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients
C Perez-Ramirez, M Canadas-Garre, A Alnatsha… - Pharmacological …, 2016 - Elsevier
Platinum-based chemotherapy is the standard treatment for NSCLC patients with EGFR wild-
type, and as alternative to failure to EGFR inhibitors. However, this treatment is aggressive …
type, and as alternative to failure to EGFR inhibitors. However, this treatment is aggressive …